Personnel Moves Archives - Page 8 of 42

Dentsply Sirona names former NuVasive CEO as board chair

Ex-NuVasive CEO Gregory Lucier will become Dentsply Sirona board chair.

Dentsply Sirona (Nasdaq:XRAY) announced today that it appointed Gregory T. Lucier as chair of its board, effective Jan. 1, 2024.

The appointment of Lucier falls in line with the company’s planned succession process and commitment to periodic board refreshment. Lucier also becomes a member of the board’s corporate governance and nominating committee when his appointment goes into effect.

Following six years as chair, Eric K. Brandt rotates from his role of non-executive chair at the end of the year. He will continue to serve as both a board member and a member of the corporate governance and nominating committee.

Lucier said in a news release that Brandt’s guidance “positioned the company well for future growth.” The newly appointed chair became a director at Dentsply Sirona in 2019. He served as CEO of Corza Health since 2018 and has more than 30 years o…

Exactech promotes from within to fill CEO spot

New CEO Darin Johnson. [Image courtesy of Exactech]Exactech announced today that it promoted Darin Johnson, the company’s president, to the position of CEO.

Johnson took over as interim CEO for the Gainesville, Florida-based orthopedic implant maker in March 2023. He now succeeds Jeffrey Binder, chair of Exactech’s board of directors.

Since joining Exactech in 2002, Johnson has held a number of executive-level leadership roles. As president, he oversaw all of the company’s business units, as well as human resources and information technologies functions. Before that, Johnson led the extremities business unit.

Over his stint at Exactech, Johnson’s experience includes building nad leading cross-functional, global teams. Those teams include orthopedic surgeons, product managers, engineers and sales professionals.

Binder highlighted Johnson’s “excellent job guiding Exactech over the past six months.” He cited yea…

Covalon announces CEO departure, search for permanent replacement

Covalon Technologies (TSXV:COV) announced today that it named Amir Boloor as interim CEO following the departure of Brian Pedlar.

Boloor serves as chair of the company’s board. As he takes on an executive role, the board appointed Joseph Cordiano to serve as lead independent director.

Mississauga, Ontario-based Covalon commenced a search for a permanent CEO. Pedlar remains on the company’s board of directors.

“On behalf of the entire board, I would like to sincerely thank Brian for his leadership during his more than 13-year tenure, including the company’s evolution from a research and development-centric company to a product-centric company. He set the stage for Covalon’s next phase of growth,” said Boloor. “We look forward to receiving his continued advice and wish him much success in his future endeavors.”

Martin Goldfarb, board member and one of Covalon’s largest shareholders, said Boloor brings a “deep understanding…

LivaNova president of cardiopulmonary is retiring

LivaNova (Nasdaq: LIVN) + announced today that Marco Dolci intends to retire from his position as president of the cardiopulmonary business unit.

Dolci plans to retire by Dec. 31, 2023, continuing in his role to support the transition of responsibilities through the end of the year. The company appointed Franco Poletti to serve as interim GM of cardiopulmonary to support the transition. He’ll do so in addition to his current role as VP of cardiopulmonary for Europe, effective immediately.

The London-based medtech company plans to retain a leading international executive search firm to help find a permanent successor. It’s another high-profile executive departure for the company, which saw CEO Damien McDonald resign in April.

LivaNova noted Dolci’s role in the progress of its Essenz perfusion system, which just last month hit another regulatory milestone.

“On behalf of the board, the exec…

TAVR tech developer JenaValve adds former J&J vet to its board

New JenaValve board member Shlomi Nachman. [Image from J&J]JenaValve Technology announced that it appointed cardiovascular industry veteran Shlomi Nachman to its board of directors.

Nachman brings more than 25 years of experience to the transcatheter aortic valve replacement (TAVR) system maker’s board. He previously held senior operating roles at Johnson & Johnson. That included serving as company group chair of cardiovascular and specialty solutions and vision groups within J&J Medical Devices.

He was a member of the company’s medical devices group operating committee as well. At J&J, Nachman led a portfolio of six different medical device businesses. Before that, he had various roles, including worldwide president of Biosense Webster and Cordis.

“We are thrilled to welcome Shlomi to the JenaValve board of directors,” said John Kilcoyne, JenaValve CEO. “His experience as both an executive and board member across innovative card…

Analysts downgrade Orthofix after the company terminates executives with cause

Orthofix (Nasdaq: OFIX) + today announced a slew of executive changes after terminating its CEO, CFO and chief legal officer with cause.

Shares of OFIX sank nearly 25% at $14.06 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell nearly 1%.

The Lewisville, Texas-based company’s board’s independent directors came to a unanimous decision to terminate the executives. Keith Valentine, John Bostjancic and Patrick Keran now depart those respective roles. The board also requested that Valentine resign from his position on the board. It plans to immediately begin a search for permanent successors.

Orthofix’s decision to terminate the executives followed an investigation conducted by independent outside legal counsel. Orthofix’s independent directors directed and oversaw the investigation. As a re…

Shockwave picks former Abbott Vascular exec Dr. Nick West as next chief medical officer

Dr. Nick West.

Shockwave Medical (Nasdaq: SWAV) + announced today that it appointed Dr. Nick West as its new associate chief medical officer.

West’s appointment marks the start of an eventual transition. He reports to the current CMO, Dr. Keith Dawkins, with intentions to succeed Dawkins in mid-2024.

“Dr. West brings to Shockwave a wealth of expertise in the interventional cardiology space,” said Dawkins. “Having known Nick for many years, I am confident that his expertise will be highly influential in further developing intravascular lithotripsy (IVL) as the standard of care for calcium modification, and will also be a valued asset in the evaluation and development of novel transformational technologies to augment our portfolio in the years to come.”

West joins Shockwave having previously served as CMO and divisional VP of global medical affairs at Abbott Vascular for four years. Before Abbott, West serve…

Inogen CFO steps down, interim replacement named

Inogen (Nasdaq:INGN) today announced that it named Mike Sergesketter as interim CFO after Kristin Caltrider stepped down.

Caltrider stepped down from the position, citing personal reasons. Her decision has no relation to any disagreements with the company or its management, operations, policies or practices. The company enlisted a leading executive search firm to begin the process of finding a permanent replacement.

Sergesketter takes on the interim post having previously assumed that role between December 2021 and March 2022. Before that, he served as CFO at Kimball Electronics.

“I would like to thank Kristin for her contributions to Inogen and share my optimism for the future of the company as we continue our strategic evolution to become a more prominent player in respiratory care,” said Nabil Shabshab, Inogen president and CEO. “Mike has brought value to Inogen as an accomplished CFO and partner to me, and I am pleased to welcome him back…

Zimmer Biomet makes a handful of executive changes under new CEO

From left: New Zimmer Biomet executive leadership team members Wilfred van Zuile, Mark Bezjack and Nitin Goyal.

Zimmer Biomet (NYSE: ZBH) + announced today that it made a number of updates to its executive leadership team.

The changes follow the recent appointment of Ivan Tornos to CEO after Bryan Hanson left for the corner office at 3M Healthcare.

Amid the changes, Zimmer Biomet named Wilfred van Zuilen group president, EMEA, and promoted Mark Bezjack to president of the Americas. Warsaw, Indiana-based Zimmer Biomet also added Chief Science, Technology and Innovation Officer Dr. Nitin Goyal to its executive leadership team. All appointments report directly to Tornos.

“The expansion of Zimmer Biomet’s executive leadership team coincides with our renewed focus on commercial execution and innovation to drive the Company forward,” said Tornos. “These appointments demonstrate the continued ev…

Cordis names former Spectranetics CEO as executive chair

Scott Drake is the new executive chair of Cordis’ board of directors [Image courtesy of Cordis]Interventional vascular tech company Cordis today announced that board member Scott Drake will be the new executive chair of its board of directors.

Drake succeeds Duke Rohlen, who served as executive chair since Hellman & Friedman and KKR acquired the company from Cardinal Health in 2021. Rohlen will stay on the company’s board of directors and will continue to serve as CEO of both the Cordis-X independent innovation accelerator and Ajax Health.

During his six-year tenure as president and CEO of the Spectranetics Corp., Drake increased shareholder value from approximately $170 million to $2.2 billion, according to Cordis. Philips acquired Spectranetics and its vascular intervention device tech for $2.2 billion in 2017. Drake is also the former chair at AtriCure.

According to the company, Drake will provide the leadership experience needed to effec…

Illumina picks a new CEO amid SEC investigation

Jacob Thaysen, Illumina’s incoming CEO [Image courtesy of Illumina]Illumina (Nasdaq: ILMN) — the DNA sequencing and array-based tech developer — has tapped an Agilent Technologies executive as its new CEO as it seeks to move beyond regulatory scrutiny of its acquisition of Grail.

Jacob Thaysen, an Agilent Technologies SVP and president of its Life Sciences and Applied Markets Group, takes over Illumina’s corner office on Sept. 25. Charles Dadswell, Illumina’s interim CEO, will resume his position as SVP and general counsel once Thaysen becomes CEO.

“After conducting a robust search process, we are thrilled to have found someone of Jacob’s caliber to become chief executive of Illumina and help shape and lead the company into its next phase of growth,” said Hologic CEO Stephen P. MacMillan, who is chair of Illumina’s board.

Illumina described Thaysen as having a long history in clinical – specifically oncology – diag…

Glucotrack tabs former Medtronic veteran for a board director spot

New Glucotrack board member Erin Carter. [Image courtesy of Erin Carter on LinkedIn]Glucotrack (Nasdaq:GCTK) announced today that it appointed Erin Carter to its board of directors, naming her chair of its audit committee.

Carter’s appointment comes just days after the implantable continuous glucose monitor (CGM) maker named Drinda Benjamin VP of marketing. She becomes a member of the board and chair of the audit committee, effective immediately.

Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes.

Get the full story at our sister site, Drug Delivery Business News.